Literature DB >> 3038761

Influence of lysophospholipids and PAF on the oxidative burst of PMNL.

W Englberger, D Bitter-Suermann, U Hadding.   

Abstract

Lysophosphatidylcholine (LC), platelet activating factor (PAF) and its precursor lysophosphatidalcholine (LP) enhance O-2-release by polymorphonuclear leucocytes (PMNL) triggered by PMA whereas lysophospholipids with other polar headgroups fail to do so. The generation of these lysophosphatidylcholine-like molecules appears to represent an essential step in the activation of the oxidative burst of the PMNL triggered by PMA since inhibition of phospholipase A2 (PLA2) by p-bromophenacylbromide (BB) or mepacrine results in an inhibition of the O-2 release. This inhibition seems to be due to the reduced generation of the phospholipids studied as it could be reversed by LP. In addition, stimulation of the oxidative burst of the PMNL by the chemotactic stimuli, N-formyl-methionyl-leucylphenylalanine (FMLP), and the complement fragment C5a could also be significantly enhanced by LP as shown by chemiluminescence. However, the response to the phagocytic stimulus, opsonized zymosan (Zx), is not affected by LP. These data provide evidence for the participation of phospholipid metabolism in the initiation of the oxidative burst of PMNL induced by the soluble monomeric stimuli PMA, FMLP and C5a.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3038761     DOI: 10.1016/0192-0561(87)90051-8

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  11 in total

1.  Anti-inflammatory, membrane-stabilizing interactions of salmeterol with human neutrophils in vitro.

Authors:  R Anderson; C Feldman; A J Theron; G Ramafi; P J Cole; R Wilson
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

2.  Evidence for the role of platelet-activating factor in immune complex vasculitis in the rat.

Authors:  J S Warren; D M Mandel; K J Johnson; P A Ward
Journal:  J Clin Invest       Date:  1989-02       Impact factor: 14.808

3.  Membrane-stabilizing, anti-inflammatory interactions of macrolides with human neutrophils.

Authors:  R Anderson; A J Theron; C Feldman
Journal:  Inflammation       Date:  1996-12       Impact factor: 4.092

4.  Roxithromycin, clarithromycin, and azithromycin attenuate the injurious effects of bioactive phospholipids on human respiratory epithelium in vitro.

Authors:  C Feldman; R Anderson; A J Theron; G Ramafi; P J Cole; R Wilson
Journal:  Inflammation       Date:  1997-12       Impact factor: 4.092

5.  Lysophosphatides enhance superoxide responses of stimulated human neutrophils.

Authors:  I Ginsburg; P A Ward; J Varani
Journal:  Inflammation       Date:  1989-04       Impact factor: 4.092

6.  Synergistic effects among oxidants, membrane-damaging agents, fatty acids, proteinases, and xenobiotics: killing of epithelial cells and release of arachidonic acid.

Authors:  I Ginsburg; R Kohen
Journal:  Inflammation       Date:  1995-02       Impact factor: 4.092

7.  Granulocyte/macrophage colony-stimulating factor affects myo-inositol metabolism in a novel manner. Implications for its priming action on human neutrophils.

Authors:  C H MacPhee
Journal:  Biochem J       Date:  1992-09-01       Impact factor: 3.857

8.  Involvement of calcium in modulation of neutrophil function by phorbol esters that activate protein kinase C isotypes and related enzymes.

Authors:  J E Merritt; K E Moores; A T Evans; P Sharma; F J Evans; C H MacPhee
Journal:  Biochem J       Date:  1993-02-01       Impact factor: 3.857

9.  Synergism among oxidants, proteinases, phospholipases, microbial hemolysins, cationic proteins, and cytokines.

Authors:  I Ginsburg; R Misgav; A Pinson; J Varani; P A Ward; R Kohen
Journal:  Inflammation       Date:  1992-10       Impact factor: 4.092

Review 10.  An Updated Review of Pro- and Anti-Inflammatory Properties of Plasma Lysophosphatidylcholines in the Vascular System.

Authors:  Eva Knuplez; Gunther Marsche
Journal:  Int J Mol Sci       Date:  2020-06-24       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.